Patent intelligence · US
US 10162933
High resolution allele identification
High resolution allele identification
Patent details — US 10162933
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 25, 2018
- Expiration
- Dec 20, 2038
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Claims
- 24
- CPC classes
- A61P, A61P43/00
Quick answer
US 10162933 (High resolution allele identification) is held by REGENERON PHARMACEUTICALS, INC.. Status: granted. Granted Dec 25, 2018. Expires Dec 20, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Expiration
- Claims
- 24
- CPC classes
- A61P, A61P43/00
More from REGENERON PHARMACEUTICALS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12421512
CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation
granted -
US 12421317
Polynucleotides encoding anti-glucagon-like peptide 1 receptor (GLP1R) antagonist antibodies
granted -
US 12421315
CLL-1 targeted immunotherapies
granted -
US 12419963
Diels-Alder conjugation methods
granted -
US 12415856
EGFR x CD28 multispecific antibodies
granted -
US 12410442
Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems
granted -
US 12404505
Delivery of a gene-editing system with a single retroviral particle and methods of generation and use
granted -
US 12402611
Genetically modified mice and engraftment
granted
Related coverage
BBSW AI Solution: Key Insights from the 2026 Event
The BBSW AI Solution event in Foster, USA, promises to unveil critical advancements in AI technology for the pharma industry. Stay tuned for live updates and key takeaways.
BBSW AI Solution 2026: Key Insights and Highlights
The BBSW AI Solution event in 2026 is set to unveil groundbreaking advancements in AI technology. Join us for live coverage and key insights from industry leaders.
Frequently asked questions
What is US patent 10162933?
US 10162933 (High resolution allele identification) is held by REGENERON PHARMACEUTICALS, INC.. Status: granted. Granted Dec 25, 2018. Expires Dec 20, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10162933?
REGENERON PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 837 pharmaceutical patents for this assignee.
When does US 10162933 expire?
Our index shows an expiration date of Dec 20, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.